BUSINESS
Balaji Amines: Does it merit a look?
BUSINESS
Divi’s Lab: Sequential improvement, but long way to go
BUSINESS
Zydus Lifesciences: Time to book profit, post strong rally over a year?
BUSINESS
Navin Fluorine: Innovator-led growth to continue in FY24 for this pricey stock
BUSINESS
Cipla: US business momentum to moderate
BUSINESS
SRF: Chemicals continue to shine, but all priced in
BUSINESS
Dr Reddy’s: Time to book profit?
BUSINESS
Aarti Industries: Is it time to look past inventory headwinds?
BUSINESS
Fed policy: Is the end in sight for the rate hike cycle?
BUSINESS
Apcotex: Gradual ramp-up of new facilities to drive earnings
BUSINESS
Laurus Labs: Is the worst priced in?
BUSINESS
Syngene: Zoetis opportunity unfolds
BUSINESS
Is Unichem deal a misstep for Ipca Labs?
BUSINESS
Mankind Pharma IPO: A pricey proposition on branded domestic pharma market
BUSINESS
Fermenta Biotech: Time to look beyond near-term cyclical challenges?
BUSINESS
Oil Update: What should investors do after the OPEC shocker?
BUSINESS
Sun Pharma: Ransomware attack to eat into operational performance
BUSINESS
Fed policy: Banking crises may turn out to be a blessing in disguise for inflation goals
BUSINESS
Can the Credit Suisse deal lend enough confidence to Fed in fighting inflation?
BUSINESS
Ami Organics: Europe plus one trend is taking hold
BUSINESS
NOCIL: What should investors do as company struggles with inventory correction?
BUSINESS
Is it time to look at this quality chemical play?
BUSINESS
Apollo Hospitals: A credible profitability road map for pharmacy is the ask
BUSINESS
Global Health: Faster ramp-up in new facilities adds to financial health
